Ivan Spasojevic

Ivan Spasojevic

Associate Professor in Medicine

Appointments and Affiliations

  • Associate Professor in Medicine
  • Member of the Duke Cancer Institute

Contact Information

  • Office Location: 5317 Orange Zone, Duke Hospital South, Durham, NC 27710
  • Office Phone: +1 919 684 8311
  • Email Address: ivan.spasojevic@duke.edu

Education

  • Ph.D. Duke University, 1999

Representative Publications

  • Lin, A; Mertens, AN; Rahman, MZ; Tan, ST; Il'yasova, D; Spasojevic, I; Ali, S; Stewart, CP; Fernald, LCH; Kim, L; Yan, L; Meyer, A; Karim, MR; Shahriar, S; Shuman, G; Arnold, BF; Hubbard, AE; Famida, SL; Akther, S; Hossen, MS; Mutsuddi, P; Shoab, AK; Shalev, I; Rahman, M; Unicomb, L; Heaney, CD; Kariger, P; Colford, JM; Luby, SP; Granger, DA, A cluster-randomized trial of water, sanitation, handwashing and nutritional interventions on stress and epigenetic programming., Nat Commun, vol 15 no. 1 (2024) [10.1038/s41467-024-47896-z] [abs].
  • Hariharan, S; Whitfield, BT; Pirozzi, CJ; Waitkus, MS; Brown, MC; Bowie, ML; Irvin, DM; Roso, K; Fuller, R; Hostettler, J; Dharmaiah, S; Gibson, EA; Briley, A; Mangoli, A; Fraley, C; Shobande, M; Stevenson, K; Zhang, G; Malgulwar, PB; Roberts, H; Roskoski, M; Spasojevic, I; Keir, ST; He, Y; Castro, MG; Huse, JT; Ashley, DM, Interplay between ATRX and IDH1 mutations governs innate immune responses in diffuse gliomas., Nat Commun, vol 15 no. 1 (2024) [10.1038/s41467-024-44932-w] [abs].
  • Zhao, J; Cochrane, CS; Najeeb, J; Gooden, D; Sciandra, C; Fan, P; Lemaitre, N; Newns, K; Nicholas, RA; Guan, Z; Thaden, JT; Fowler, VG; Spasojevic, I; Sebbane, F; Toone, EJ; Duncan, C; Gammans, R; Zhou, P, Preclinical safety and efficacy characterization of an LpxC inhibitor against Gram-negative pathogens., Sci Transl Med, vol 15 no. 708 (2023) [10.1126/scitranslmed.adf5668] [abs].
  • Ozer, I; Slezak, A; Sirohi, P; Li, X; Zakharov, N; Yao, Y; Everitt, JI; Spasojevic, I; Craig, SL; Collier, JH; Campbell, JE; D'Alessio, DA; Chilkoti, A, An injectable PEG-like conjugate forms a subcutaneous depot and enables sustained delivery of a peptide drug., Biomaterials, vol 294 (2023) [10.1016/j.biomaterials.2022.121985] [abs].
  • Soares, RB; Manguinhas, R; Costa, JG; Saraiva, N; Gil, N; Rosell, R; Camões, SP; Batinic-Haberle, I; Spasojevic, I; Castro, M; Miranda, JP; Amaro, F; Pinto, J; Fernandes, AS; Guedes de Pinho, P; Oliveira, NG, MnTnHex-2-PyP5+ Displays Anticancer Properties and Enhances Cisplatin Effects in Non-Small Cell Lung Cancer Cells., Antioxidants (Basel), vol 11 no. 11 (2022) [10.3390/antiox11112198] [abs].